Conjunctival Transpositional Surgery for Primary Pterygium

NCT ID: NCT07343011

Last Updated: 2026-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-21

Study Completion Date

2027-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective single-arm interventional study evaluates the recurrence rate and functional outcomes following conjunctival transpositional pterygium surgery without bare sclera formation. The technique involves mobilization and transposition of the pterygium tissue while preserving Tenon's layer and avoiding adjunctive therapies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pterygium of the Conjunctiva and Cornea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pterygium patients

Group Type EXPERIMENTAL

Conjunctival Transpositional Pterygium Surgery

Intervention Type PROCEDURE

A conjunctival incision was created at the upper and lower limbus to allow adequate tissue mobilization. The pterygium tissue is dissected off the corneal surface without complete excision or creation of a bare sclera defect. The fibrovascular tissue is mobilized and transposed inferiorly within the subconjunctival plane and secured with absorbable sutures. Tenon's tissue is preserved, and no adjunctive therapy is used.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conjunctival Transpositional Pterygium Surgery

A conjunctival incision was created at the upper and lower limbus to allow adequate tissue mobilization. The pterygium tissue is dissected off the corneal surface without complete excision or creation of a bare sclera defect. The fibrovascular tissue is mobilized and transposed inferiorly within the subconjunctival plane and secured with absorbable sutures. Tenon's tissue is preserved, and no adjunctive therapy is used.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 18 years or older
* Primary pterygium involving the cornea
* Ability to provide informed consent

Exclusion Criteria

* Recurrent pterygium
* Previous ocular surface surgery
* Active ocular infection or inflammation
* Severe ocular surface disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zahedan University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohammed Arish

Associate professor of ophthalmology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alzahra Eye Hospital, Zahedan University of Medical Sciences

Zahedan, Sistan and Balochistan, Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohammed Arish, MD, FRCS

Role: CONTACT

09151419155

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohammed Arish, MD, FRCS

Role: primary

09151419155

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IR.ZAUMS.REC.1404.238

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.